Sign Out
Reproduction studies in animals (mice and rats) with orally and parenterally administered Co-Amoxiclav have shown no teratogenic effects. There is limited experience of the use of Co-Amoxiclav in human pregnancy. As with all medicines, use should be avoided in pregnancy, especially during the 1st trimester, unless considered essential by the physician.
Co-Amoxiclav may be administered during the period of lactation. Except for the risk of sensitization associated with the excretion of trace quantities in breast milk, there are no detrimental effects for the breastfed infant.
